India’s life sciences industry is accelerating its transition from a global hub for generic drug manufacturing to a center for novel drug discovery, according to a new report by Boston Consulting Group (BCG) and HealthKois Partners. The findings, reviewed by Herald Express, reveal a 40% increase in the number of innovative drug candidates entering clinical trials over the past three years, with Indian firms advancing molecules in oncology, metabolic disorders, and infectious diseases. While challenges remain—including regulatory bottlenecks and funding gaps—the report signals a potential transformation in India’s pharmaceutical sector, one that could redefine its role in the global healthcare ecosystem.
What Happened
The BCG-HealthKois report, titled “India’s Emerging Role in Novel Drug Discovery: A Strategic Pivot,” provides the first comprehensive analysis of India’s evolving pharmaceutical R&D landscape. Key findings include:
– Expanding Pipeline: Indian companies now have over 120 novel drug candidates in clinical development, a 38% increase since 2023. Of these, 18 molecules have progressed to Phase II or Phase III trials, with oncology (42% of the pipeline) and metabolic disorders (28%) as the dominant therapeutic areas.
– Corporate Investments: Major domestic players—including Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Biocon, and Glenmark Pharmaceuticals—have collectively increased R&D spending by 22% year-over-year, with a focus on biologics, small molecules, and cell-based therapies.
– Global Collaborations: Indian firms are partnering with multinational pharmaceutical companies and academic institutions to accelerate drug development. Notable examples include Biocon’s collaboration with Serum Institute of India on a novel diabetes therapy and Dr. Reddy’s partnership with a U.S.-based biotech firm for an experimental cancer drug.
– Government Support: The Indian government’s Production-Linked Incentive (PLI) scheme for pharmaceuticals, launched in 2021, has allocated ₹15,000 crore (approximately $1.8 billion) to boost domestic manufacturing and R&D. Additionally, the Biotechnology Industry Research Assistance Council (BIRAC) has funded over 200 biotech startups since 2022, many focused on drug discovery.
The report also highlights a surge in patent filings by Indian firms, with the Indian Patent Office recording a 15% increase in pharmaceutical patent applications in 2025 compared to 2023. This trend underscores a shift toward intellectual property (IP)-driven growth, moving away from India’s historical reliance on generic drug production.
Why It Matters
India’s pharmaceutical industry has long been a cornerstone of the global generics market, supplying nearly 20% of the world’s generic drugs by volume. However, the sector’s heavy dependence on off-patent medicines has left it vulnerable to pricing pressures and margin erosion. The pivot toward novel drug discovery could address these challenges while unlocking new economic opportunities:
1. Economic Diversification: The global market for novel drugs is projected to reach $1.5 trillion by 2030, with high-margin biologics and specialty therapies driving growth. India’s entry into this space could reduce its reliance on generics and create high-value jobs in R&D, manufacturing, and clinical trials.
2. Healthcare Sovereignty: Developing indigenous therapies could improve access to cutting-edge treatments for India’s 1.4 billion people, particularly in areas like oncology and rare diseases, where domestic innovation has historically lagged.
3. Global Competitiveness: Success in novel drug discovery could elevate India’s standing in the global pharmaceutical value chain, positioning it alongside established innovation hubs like the U.S., Europe, and China. The report notes that India’s cost advantages—R&D expenses are 30-40% lower than in Western markets—could make it an attractive destination for outsourced drug development.
4. Geopolitical Leverage: As global supply chains face disruptions, India’s growing R&D capabilities could strengthen its strategic position in healthcare diplomacy, particularly with countries seeking alternatives to Chinese and Western pharmaceutical dominance.
Background and Context
India’s pharmaceutical industry has undergone multiple transformations since its emergence in the 1970s. Key milestones include:
– 1970s-1990s: The Generics Revolution: India’s adoption of process patents (rather than product patents) under the Patents Act of 1970 enabled domestic firms to reverse-engineer and manufacture affordable generic versions of patented drugs. This policy, combined with low production costs, positioned India as the “pharmacy of the developing world.”
– 2005: TRIPS Compliance: India’s accession to the World Trade Organization (WTO) and compliance with the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement forced a shift toward product patents, compelling firms to either license drugs or invest in innovation.
– 2010s: The Biosimilars Push: Indian companies like Biocon and Dr. Reddy’s began investing in biosimilars—generic versions of biologic drugs—capitalizing on the expiration of patents for blockbuster biologics like Humira and Herceptin. This period also saw increased R&D spending, though primarily focused on incremental innovation rather than first-in-class therapies.
– 2020s: The Novel Drug Discovery Era: The COVID-19 pandemic exposed vulnerabilities in global pharmaceutical supply chains, accelerating India’s push toward self-reliance (Atmanirbhar Bharat). Government incentives, coupled with a maturing biotech ecosystem, have created a fertile environment for novel drug development.
Despite these advancements, India’s share of the global novel drug market remains negligible—less than 1% compared to the U.S. (50%) and Europe (25%). The BCG-HealthKois report suggests that closing this gap will require sustained investment in three key areas:
– Talent Development: India produces over 150,000 STEM graduates annually, but the report notes a shortage of skilled researchers in translational medicine and clinical pharmacology.
– Regulatory Reforms: The Central Drugs Standard Control Organization (CDSCO) has faced criticism for slow approval processes, with the average time for clinical trial approvals exceeding 12 months—nearly double the global average. Streamlining these processes could accelerate drug development.
– Funding Ecosystem: While venture capital funding for Indian biotech startups reached $1.2 billion in 2025 (up from $300 million in 2020), the report highlights a need for more long-term capital, particularly for early-stage research.
Competing Claims and Uncertainty
While the BCG-HealthKois report paints an optimistic picture of India’s drug discovery ambitions, industry experts and analysts offer divergent perspectives on the sector’s readiness to compete globally:
1. Optimistic View: Proponents argue that India’s cost advantages, growing talent pool, and government support create a unique opportunity to disrupt the global pharmaceutical landscape. Dr. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, stated in a recent interview that “India’s biotech sector is at an inflection point, with the potential to become a $150 billion industry by 2030 if R&D investments continue to grow.” She cited Biocon’s success in developing a novel oral insulin candidate as evidence of India’s capabilities in complex biologics.
2. Skeptical View: Critics caution that India’s drug discovery ecosystem remains nascent compared to established hubs. Dr. Reddy’s Laboratories, for instance, has faced setbacks in its novel drug pipeline, including the failure of its experimental Alzheimer’s drug in Phase II trials in 2024. Some analysts question whether Indian firms can sustain the high-risk, high-reward nature of drug discovery, given the sector’s historical focus on low-margin generics.
3. Regulatory Concerns: The CDSCO has taken steps to modernize its approval processes, including the launch of a digital portal for clinical trial applications in 2025. However, industry stakeholders argue that bureaucratic hurdles persist. A 2025 survey by the Indian Pharmaceutical Alliance (IPA) found that 68% of pharmaceutical executives cited regulatory delays as the biggest obstacle to innovation.
4. Global Competition: India’s emergence as a drug discovery hub coincides with intensified competition from China, which has rapidly expanded its biotech sector with state-backed funding and relaxed regulatory pathways. China’s share of global clinical trials has grown from 5% in 2015 to 18% in 2025, raising questions about India’s ability to attract multinational partnerships.
5. Funding Gaps: While venture capital funding for Indian biotech has grown, early-stage research remains underfunded. A 2025 report by Bain & Company found that 70% of Indian biotech startups struggle to secure Series A funding, compared to 40% in the U.S. and Europe. This funding gap could limit the pipeline of innovative therapies.
What to Watch Next
The trajectory of India’s novel drug discovery efforts will hinge on several critical developments in the coming years:
1. Regulatory Reforms: The CDSCO’s ability to streamline clinical trial approvals and align with global standards (e.g., ICH guidelines) will be pivotal. The government’s proposed Drugs, Medical Devices, and Cosmetics Bill, 2026, which aims to overhaul India’s regulatory framework, could either accelerate or hinder progress depending on its implementation.
2. Corporate Strategies: The success of Indian firms in advancing drug candidates through Phase III trials and securing global partnerships will serve as a litmus test for the sector’s maturity. Key molecules to watch include:
– Biocon’s Insulin Tregopil: An oral insulin candidate in Phase III trials for Type 2 diabetes, with potential to disrupt the $30 billion global insulin market.
– Sun Pharma’s SUN-1334: A novel small-molecule therapy for psoriasis, currently in Phase II trials in the U.S. and Europe.
– Glenmark’s GBR 1342: A first-in-class bispecific antibody for multiple myeloma, developed in collaboration with a Swiss biotech firm.
3. Government Policies: The continuation of the PLI scheme and additional incentives for R&D could provide much-needed momentum. The report recommends expanding the scheme to include tax breaks for clinical trial expenses and grants for early-stage research.
4. Global Partnerships: India’s ability to attract collaborations with multinational pharmaceutical companies will be critical. Recent deals, such as Dr. Reddy’s partnership with a U.S. firm for a novel oncology drug, suggest growing interest from global players. However, India will need to demonstrate a track record of successful drug launches to sustain these partnerships.
5. Talent Development: Addressing the shortage of skilled researchers in translational medicine will require investments in education and training. Initiatives like the National Biopharma Mission, which aims to create a pipeline of 50,000 skilled biotech professionals by 2030, could play a key role.
6. Market Access: Even if Indian firms succeed in developing novel drugs, securing reimbursement and market access in key markets like the U.S. and Europe will be challenging. The report highlights the need for Indian companies to build commercialization capabilities, including sales and marketing infrastructure.
Conclusion
India’s life sciences sector stands at a crossroads, with the potential to transition from a generics powerhouse to a global leader in novel drug discovery. The BCG-HealthKois report provides compelling evidence of progress, from the expansion of clinical pipelines to increased R&D investments and government support. However, the path forward is fraught with challenges, including regulatory bottlenecks, funding gaps, and fierce global competition.
The coming decade will determine whether India can sustain its momentum and emerge as a credible player in the high-stakes world of drug innovation. Success will require not only continued investment but also structural reforms to address the sector’s long-standing weaknesses. If achieved, this transformation could reshape India’s
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Google News India — source.
